Tech Company Financing Transactions
MucoLife Therapeutics Funding Round
MucoLife Therapeutics secured a $98 thousand funding round on 11/6/2026. Investors included Vinnova.
Transaction Overview
Company Name
Announced On
11/6/2026
Transaction Type
Debt
Amount
$98,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds will help establish high-purity manufacturing controls, lower technical and financial risks, and act as a crucial prerequisite to advance the preclinical candidate into upcoming toxicology studies and clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Erik Dahlbergsgatan 11A
Gothenburg, 411 26
Sweden
Gothenburg, 411 26
Sweden
Phone
Website
Email Address
Overview
MucoLife Therapeutics was born from a shared passion to revolutionize the treatment of mucus obstruction in chronic lung diseases that affect millions across the globe. Founded by researcher and visionary entrepreneurs from the Mucin Biology Groups at University of Gothenburg, we leverage 40 years of groundbreaking research in mucin biology to bring benefit for the patients. We are developing a pipeline of innovative medications targeting obstructive mucus accumulation in COPD and other chronic lungs diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/6/2026: OpenAI venture capital transaction
Next: 11/6/2026: Synctera venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








